featured
Cardiovascular Outcomes With a Novel GLP-1 Receptor Agonist Efpeglenatide in Type 2 DM
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: